5243482026-11-065243482026-11-06ActionsTakenOrOrdersPassedDomain15243482026-11-06ActionsTakenOrOrdersPassedDomain1PersonsAgainstWhomActionsTakenOrOrdersPassedDomain15243482026-11-06SignatoriesDomain1xbrli:pureAARTIDRUGSAARTI DRUGS LIMITED524348NOTLISTEDINE767A01016NewAction(s) taken or orders passed (sub-para 20)false2026-11-0615:00:002026-11-06Any other similar action(s)United States Food and Drug Administration (“US FDA”) has inspected the Formulations manufacturing facility of our Subsidiary, Pinnacle Life Science Private Limited at Baddi, Himachal Pradesh from 2nd to 6th of November 2026. On conclusion of the inspection, the company has received 3 inspectional observations in Form 483, where none of the observations are related to Data Integrity. The company will work closely with US FDA in resolving all points. Regulatory AuthorityUnited States Food and Drug Administration (“US FDA”)1SubsidaryPinnacle Life Science Private LimitedForm 483United States Food and Drug Administration (“US FDA”) has inspected the Formulations manufacturing facility of our Subsidiary, Pinnacle Life Science Private Limited at Baddi, Himachal Pradesh from 2nd to 6th of November 2026. On conclusion of the inspection, the company has received 3 inspectional observations in Form 483, where none of the observations are related to Data Integrity. The company will work closely with US FDA in resolving all points. 2026-11-06United States Food and Drug Administration (“US FDA”) has inspected the Formulations manufacturing facility of our Subsidiary, Pinnacle Life Science Private Limited at Baddi, Himachal Pradesh from 2nd to 6th of November 2026. On conclusion of the inspection, the company has received 3 inspectional observations in Form 483, where none of the observations are related to Data Integrity. The company will work closely with US FDA in resolving all points. not applicableThere is no impact on financial, operation or other activities of Pinnacle pursuant the above communication.On conclusion of the inspection, the company has received 3 inspectional observations in Form 483, where none of the observations are related to Data Integrity. The company will work closely with US FDA in resolving all points.not applicablenot applicableThe company will work closely with US FDA in resolving all pointsRushikesh DeoleCompany Secretary2026-11-06Mumbai